LARIMAR THERAPEUTICS INC LRMR 深 滬
等待開盤 09-23 09:30:00 美东时间
4.48
+0.280
+6.67%
華盛通- 最 高4.58
- 今 開4.16
- 成交量 271.55万股
- 最 低 4.06
- 昨 收 4.20
- 總市值 3.83亿
- 52周最高 9.50
- 市盈率 靜 --
- 換手率 3.17%
- 52周最低 1.61
- 委 比 -18.80%
- 總股本 8559.04万
- 歷史最高 664.32
- 量 比 1.89
- 振 幅 12.38%
- 歷史最低 1.53
- 每 手 1
- 風險率 1.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多JMP Securities Maintains Market Outperform on Larimar Therapeutics, Lowers Price Target to $18
JMP Securities analyst Jonathan Wolleben maintains Larimar Therapeutics (NASDAQ:LRMR) with a Market Outperform and lowers the price target from $22 to $18.
08-15 21:25
Larimar Therapeutics Q2 EPS $(0.41) Beats $(0.48) Estimate
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.48) by 14.76 percent. This is a 20.59 percent decrease over losses of $(0.34) per share
08-14 19:16
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
Larimar Therapeutics, Inc. completed an underwritten public offering of 21.56 million shares of its common stock, including 2.81 million additional shares, at $3.20 per share, raising $69 million in gross proceeds. The company plans to use the funds to develop its pipeline, including nomlabofusp for Friedreich’s ataxia, and for general corporate purposes.
07-31 20:15
Larimar Therapeutics Announces $64.4 Million Stock Offering
Larimar Therapeutics ( ($LRMR) ) has provided an update. On July 29, 2025, Lari...
07-31 18:29
Larimar Therapeutics prices $60M stock offering
Larimar Therapeutics (NASDAQ:LRMR) has priced its underwritten public offering of 18.75 million shares at $3.20 per share, expecting to raise $60 million in gross proceeds. The company has also grante...
07-30 12:09
Larimar Therapeutics shares are trading lower after the company announced a proposed underwritten public offering.
Larimar Therapeutics shares are trading lower after the company announced a pro...
07-30 04:04
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
Larimar Therapeutics announced the pricing of its public offering of 18,750,000 shares at $3.20 per share, expecting to raise $60 million. Additionally, underwriters have a 30-day option to purchase up to 2,812,500 more shares. Proceeds will support drug development for rare diseases, including nomlabofusp, and general corporate purposes. The offering is underwritten by Leerink Partners, Guggenheim Securities, Truist Securities, and William Blair...
07-30 03:50
Larimar Highlights Data for Rare Disease Drug Nomlabofusp in FDA Briefing
Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication of two peer-reviewed articles
07-08 19:09
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia
<p>Larimar Therapeutics has published two peer-reviewed articles detailing nonclinical data on nomlabofusp, a potential treatment for Friedreich’s ataxia. The studies demonstrate the drug's mechanism of action, its ability to increase FXN protein levels in key tissues, and support the use of skin FXN concentrations as a surrogate endpoint for accelerated approval. The company plans to submit a BLA for nomlabofusp in Q2 2026.</p>
07-08 11:00
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
